Esen Mustafa, Demirbaş Abdullah, Diremsizoglu Esin
Department of Dermatology, Faculty of Medicine Hospital, Dicle University, Diyarbakır, Turkey.
Department of Dermatology, Faculty of Medicine Hospital, Kocaeli University, Kocaeli, Turkey.
Arch Dermatol Res. 2025 Apr 17;317(1):715. doi: 10.1007/s00403-025-04231-w.
Chronic spontaneous urticaria (CSU) impacts both physical and mental well-being, causing distress and sleep disturbances. While omalizumab reduces disease activity, its effects on mental health and quality of life remain unclear. This study assesses the psychosocial burden and sleep disturbances in CSU patients receiving omalizumab compared to healthy controls and explores their relationship with disease parameters. This case--control study included 210 CSU patients receiving omalizumab for at least three months and 210 age- and sex-matched healthy controls. Disease severity was assessed using the Urticaria Activity Score over 7 Days (UAS7) and Urticaria Control Test (UCT), while quality of life was evaluated with the Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL). Psychological distress and sleep disturbances were measured using validated scales, including the Perceived Stress Scale (PSS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). CSU patients had significantly higher scores for perceived stress, depression, anxiety, and daytime sleepiness compared to controls (p < 0.001). Patients with a good response to omalizumab also showed significantly higher psychological distress and poorer sleep quality than controls (p < 0.001). Omalizumab response was good in 29.5%, moderate in 38.6%, and limited in 31.9% of patients. Despite treatment, 32.9% reported no change in quality of life, while 35.7% had mild and 31.4% had moderate improvement. A history of atopic disease was present in 55.7% of patients, who had significantly higher daytime sleepiness scores than those without (p = 0.045). In CSU patients, while omalizumab improves symptoms and quality of life, psychological distress persists in substantial subsets, highlighting the need to address mental health and lifestyle factors.
慢性自发性荨麻疹（CSU）会影响身心健康，导致痛苦和睡眠障碍。虽然奥马珠单抗可降低疾病活动度，但其对心理健康和生活质量的影响仍不明确。本研究评估了接受奥马珠单抗治疗的CSU患者与健康对照者相比的心理社会负担和睡眠障碍，并探讨了它们与疾病参数之间的关系。这项病例对照研究纳入了210例接受奥马珠单抗治疗至少三个月的CSU患者以及210例年龄和性别匹配的健康对照者。使用7天荨麻疹活动评分（UAS7）和荨麻疹控制测试（UCT）评估疾病严重程度，同时用慢性荨麻疹生活质量问卷（CU-Q₂oL）评估生活质量。使用经过验证的量表测量心理困扰和睡眠障碍，包括感知压力量表（PSS）、贝克抑郁量表（BDI）、贝克焦虑量表（BAI）、匹兹堡睡眠质量指数（PSQI）和爱泼华嗜睡量表（ESS）。与对照组相比，CSU患者在感知压力、抑郁、焦虑和日间嗜睡方面的得分显著更高（p<0.001）。对奥马珠单抗反应良好的患者与对照组相比，也表现出显著更高的心理困扰和更差的睡眠质量（p<0.001）。29.5%的患者对奥马珠单抗反应良好，38.6%为中度反应，31.9%为有限反应。尽管接受了治疗，32.9%的患者报告生活质量没有变化，而35.7%有轻度改善，31.4%有中度改善。55.7%的患者有特应性疾病史，他们的日间嗜睡得分显著高于无特应性疾病史的患者（p=0.0
